Wanbury Limited Reports No DMF Issues From USFDA and Explores South Korea Opportunities

Market snapshot: Mumbai-headquartered active pharmaceutical ingredients manufacturer Wanbury Limited has announced a key regulatory milestone. The company has received a deficiency-free Drug Master File status letter from the USFDA covering multiple Abbreviated New Drug Applications for Metformin Hydrochloride. Simultaneously, the company is solidifying its international footprint by filing another DMF to access emerging opportunities in South Korea.

Data Snapshot

• Wanbury received a deficiency-free DMF letter from the USFDA covering multiple Metformin Hydrochloride ANDA formulations.
• The company reported a 116.6% YoY increase in audited net profit to ₹66.1 cr for the full fiscal year FY26.
• Wanbury completed the full early redemption of 12.5% Non-Convertible Debentures representing a principal amount of ₹180 cr on July 15, 2026.
• Borrowing costs reduced to sub-10% p.a. from July 1, 2026, following a debt takeover by Axis Finance and Poonawalla Fincorp, releasing a 40.65% promoter share pledge.

What's Changed

• FY26 net profit improved to ₹66.1 cr from ₹30.5 cr in FY25, representing a growth of ≈116.7% YoY (derived: ₹66.1 cr vs ₹30.5 cr).
• FY26 revenue from operations increased to ₹650.3 cr compared to ₹599.5 cr in the previous fiscal year, a growth of ≈8.5% YoY.
• EBITDA rose to ₹107.7 cr in FY26 from ₹79.8 cr in FY25, representing a growth of ≈35% (derived: ₹107.7 cr vs ₹79.8 cr).

Key Takeaways

• The 'No DMF deficiency' status from the USFDA removes regulatory bottlenecks for formulation clients, enhancing Wanbury's standing in the Metformin bulk market.
• Filing a new Drug Master File (DMF) in South Korea targets a transition toward high-margin, entry-barrier global markets.
• Extensive balance sheet deleveraging has successfully unlocked 40.65% of pledged equity shares and dropped borrowing rates to under 10% per annum.

SAHI Perspective

Wanbury's successful acquisition of a deficiency-free DMF letter for Metformin is highly strategic. Metformin remains a competitive bulk therapeutic arena where absolute compliance reliability determines contract longevity. This clean status from the USFDA provides its formulation partners a friction-free pathway to progress their ANDAs. Additionally, the pivot toward South Korea, following a prior zero-observation MFDS inspection at its Patalganga facility, aligns with plans to diversify product margins. Supported by a drastic reduction in debt costs and the redemption of ₹180 cr in NCDs, the company's financial risk profile has lowered considerably, enabling faster reinvestments into specialized segments.

Market Implications

With the USFDA validation, Wanbury can expect steady order pipelines from its US generic buyers. The commercial opening in South Korea offers high-potential margin growth that offsets regional concentration. It also mitigates near-term friction from the six USFDA observations received during the Tanuku facility audit in July 2026, showcasing strong overall compliance systems across its multiple plants.

Trading Signals

Market Bias: Bullish

The clean USFDA review for Metformin HCl secures critical US sales pipelines. Coupled with stellar FY26 net profits of ₹66.1 cr (+116.6% YoY) and the full early redemption of ₹180 cr in high-cost debt, the company's turnaround narrative remains highly intact.

Overweight: Pharmaceuticals, Active Pharmaceutical Ingredients (APIs)

Trigger Factors:

• Timely submission and resolution of the six USFDA observations at the Tanuku facility.
• Volume growth in shipments to South Korea following the new API DMF filing.
• Q1 FY27 results displaying the positive impact of sub-10% p.a. borrowing costs.

Time Horizon: Medium-term (3-12 months)

Industry Context

The global API sector continues to demand rigorous regulatory alignment. Metformin is one of the most widely used antidiabetic molecules globally, demanding cost-competitiveness and continuous compliance. As traditional Western generic spaces become highly saturated, Indian API exporters are looking to geographies like South Korea and South-East Asia to capture premium generic markets with high-quality regulatory filings.

Key Risks to Watch

• Increased near-term regulatory workloads to clear the six compliance observations at the Tanuku site.
• High legacy revenue dependency on mass-market molecules like Metformin and Sertraline.
• Geopolitical friction or logistic blockades affecting shipping and API dispatches to distant export hubs.

Recent Developments

Between July 13 and July 17, 2026, the USFDA inspected Wanbury's Tanuku facility, issuing six observations under Form 483. On July 15, 2026, the Board approved the early redemption of its 12.5% Non-Convertible Debentures representing a principal amount of ₹180 cr. In late June 2026, Axis Finance and Poonawalla Fincorp refinanced existing debts below 10% interest p.a., releasing 40.65% promoter group shares from pledge.

Closing Insight

Wanbury's clean regulatory status on Metformin HCl is an excellent operational validation. Bolstered by aggressive debt refinancing, the release of promoter pledges, and strategic geographic expansion, Wanbury is effectively building a highly resilient, globally compliant API footprint.

High Performance Trading with SAHI.